Theriva Biologics, Inc. (TOVX)
0.196
+0.01
(+3.16%)
USD |
NYAM |
Oct 23, 16:00
0.1916
0.00 (0.00%)
After-Hours: 20:00
Theriva Biologics Enterprise Value : 1.211M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.211M |
| October 22, 2026 | 0.9356M |
| October 21, 2026 | 1.238M |
| October 20, 2026 | 1.762M |
| October 19, 2026 | 1.610M |
| October 16, 2026 | 1.757M |
| October 15, 2026 | 1.945M |
| October 14, 2026 | 1.849M |
| October 13, 2026 | 2.115M |
| October 12, 2026 | 2.285M |
| October 09, 2026 | 2.175M |
| October 08, 2026 | 2.638M |
| October 07, 2026 | 2.955M |
| October 06, 2026 | 2.404M |
| October 05, 2026 | 2.542M |
| October 02, 2026 | 2.546M |
| October 01, 2026 | 2.542M |
| September 30, 2026 | 2.542M |
| September 29, 2026 | 1.854M |
| September 28, 2026 | 2.152M |
| September 25, 2026 | 2.340M |
| September 24, 2026 | 2.794M |
| September 23, 2026 | 2.987M |
| September 22, 2026 | 2.808M |
| September 21, 2026 | 2.808M |
| Date | Value |
|---|---|
| September 18, 2026 | 2.932M |
| September 17, 2026 | 3.322M |
| September 16, 2026 | 2.588M |
| September 15, 2026 | 2.546M |
| September 14, 2026 | 3.028M |
| September 11, 2026 | 3.579M |
| September 10, 2026 | 3.354M |
| September 09, 2026 | 3.643M |
| September 08, 2026 | 3.556M |
| September 04, 2026 | 3.827M |
| September 03, 2026 | 3.827M |
| September 02, 2026 | 3.602M |
| September 01, 2026 | 3.643M |
| August 31, 2026 | 3.689M |
| August 28, 2026 | 3.464M |
| August 27, 2026 | 3.804M |
| August 26, 2026 | 3.377M |
| August 25, 2026 | 3.116M |
| August 24, 2026 | 3.005M |
| August 21, 2026 | 3.001M |
| August 20, 2026 | 2.780M |
| August 19, 2026 | 2.560M |
| August 18, 2026 | 2.565M |
| August 17, 2026 | 3.120M |
| August 14, 2026 | 2.680M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.217M |
| Total Expenses (Quarterly) | 3.217M |
| EPS Diluted (Quarterly) | -0.0701 |
| Earnings Yield | -341.2% |
| Normalized Earnings Yield | -348.72 |